Two Innovative Events for Accelerating Science and Data Interpretations into Effective Treatments November 5-6, 2015 Hilton San Francisco Union Square Hotel San Francisco, CA Propelling Discovery through Genomic Data Identify trends, paths and abnormalities to create more effective treatments through genomic and biomarker data analysis n Improve response rates by identifying abnormalities and mutations that trigger, impact, or accelerate the disease state n Utilize genomic and phenotypic data to discover potential treatments based on genetic patterns, trends and indicators n Accelerate discovery efforts by utilizing novel techniques and technologies to understand, manipulate and treat diseases Samantha Maragh, NIST Assessing Sources of Assay Variability Accelerating Discovery and Development Through Genomics Aris N. Economides, Ph.D., Regeneron Pharmaceuticals, Inc. n Advances in Biomarkers and Breakthrough Therapeutics Leverage the discovery and identification of predictive biomarkers and liquid biopsies to accelerate disease treatments n Utilize predictive biomarkers and genetic indicators to identify diseases at a much earlier stage n Leverage big data as a discovery tool to identify potential trends and patterns that can lead to new treatments and cures n Improve biomarker discovery and development by learning about breakthroughs with cell-free biomarkers, liquid biopsies, and microrna n Detecting Expression of Oncology Targets Steven Pirie-Shepherd, Ph.D., Pfizer, Inc. Mohammad M. Afshar, Ariana Pharma Utilizing Big Data in Discovery Organized by:
Combining Genomic Data with Biomarker Discovery to Accelerate Innovative and Effective Treatments IBC s : Propelling Discovery through Genomic Data will provide you focused learning on how to utilize genomic data to identify abnormalities, mutations, patterns or trends within a disease. Hear practical case studies on recent genomic projects to help you discover new treatments, improve response rates, and validate indications of use for existing treatments. Leverage today s cuttingedge genomic data to ensure that the right patient receives the right treatment at the right time, every time. IBC s : Advances in Biomarkers and Breakthrough Therapeutics leverages the discovery and identification of biomarkers, predictive biomarkers, and liquid biopsies to understand and develop treatments for diseases at a much earlier stage. Hear global drug discovery experts present the latest developments in biomarkers to accelerate discovery efforts and achieve clinical success. Who Should Attend: These highly practical and technical conferences are specially designed for scientists, managers, directors and executives working in: Precision Medicine Personalized Medicine Translational Medicine Genomic Medicine Bioinformatics Genomic Data/Data Science Preclinical R&D Translational Discovery Cell Biology Research Biomarker Discovery Oncology Biomarkers Biomarker Development Oncology Immunology Cancer Biology Molecular Biology Clinical Affairs Antibodies Upgrade to the All Access Pass Whether your focus is in genomic data or biomarker discovery, it is critical for your organization to understand the science presented in each meeting as it directly impacts the work presented in the co-located meeting. Register your team for the All Access Pass today to gain a comprehensive overview of the genomic data and biomarker science you need to successful develop next-generation disease treatments. Meet Your Next Partner to Develop Next-Generation Disease Treatments Accelerate your research and discovery efforts by collaborating with global genomic and biomarker experts during dedicated networking luncheons, evening receptions and scientific poster viewing breaks. Both events include more than six hours of dedicated networking opportunities, allowing you to exchange best practices with like-minded researchers and meet potential partners who can advance your treatments towards clinical success and beyond. Present a Poster to Showcase Your Novel Research Share your latest research by presenting a scientific poster during the event. All posters will be displayed for fellow attendees to view and discuss. Submit your abstract online today at either event website. The deadline to submit your poster abstract is October 2, 2015.
THURSDAY, NOVEMBER 5, 2015 7:00 Registration and Coffee 8:00 Chairperson s Opening Remarks Samantha Maragh, Ph.D., Human Geneticist & Molecular Biologist, National Institute of Standards & Technology 8:15 Predicting Responses to Immunotherapy Gary C. Starling, Ph.D., Associate Vice President, Biologics Discovery Operations, Merck Research Laboratories 9:00 Using Big Data to Interpret Genomes for Diagnosis, Therapeutics, and Precision Medicine Rong Chen, Director, Clinical Genome Informatics, Genetics, and Genomic Sciences, Icahn School of Medicine, Mount Sinai 9:45 Networking and Refreshment Break in Poster and Exhibit Hall Pre-Analytical Factors for Discovery and Development 10:15 Are You Sure You Got It Right? Assessing Sources of Assay Variability and Improving Confidence Samantha Maragh, Ph.D., Human Geneticist & Molecular Biologist, National Institute of Standards & Technology 10:45 Pharmacogenetics in Drug Development to Improve Decision Making in Clinical Development Peter Shaw, Senior Director, Molecular Profiling and Pharmacogenetics, Merck Using Genomic and Biomarker Data to Identify Abnormalities and Mutations 11:15 Utilizing Genetic Indicators for Early Diagnosis of Kidney Cancer Alexander Parker, Ph.D., Cecilia and Dan Carmichael Family Associate Director for the Center of Individualized Medicine in Florida, Vice Chair, Department of Health Sciences Research, Mayo Clinic 11:45 From Genomics to Clinical Medicine: Application of ChIP-seq data to Prognosis Prediction in Cancer Chao Cheng, Ph.D., Assistant Professor, Department of Genetics, Institute for Quantitative Biomedical Sciences, Norris Cotton Cancer Center, Geisel School of Medicine, Dartmouth 12:15 Technology Workshop 12:45 Luncheon in the Poster and Exhibit Hall 1:55 Chairperson s Remarks Using Phenotypic Data for Target Validation 2:00 Variants to Targets: Translating Human Genetic Discoveries into Testable Therapeutic Hypotheses 2:30 Non-Coding RNA and Precision Medicine Prasun Mishra, Principal Investigator, Genentech 3:00 Spotlight Presentation 3:30 Networking and Refreshment Break in Poster and Exhibit Hall Improving Response Rates and Efficacy from Genomic Data 4:00 Natural Aromatase Inhibitor Combinations for Targeting Breast Cancer Sandeep Kumar Shukla, Research Scholar, School of Engineering, Indian Institute of Technology Mandi 4:30 Strategies for Optimizing Data for Samantha Maragh, Ph.D., Human Geneticist & Molecular Biologist, National Institute of Standards & Technology Prasun Mishra, Principal Investigator, Genentech 5:00 Networking Reception in Poster and Exhibit Hall Bridging the Gap Between and Diagnostics through Biomarkers 10:15 Strategies for Accelerating Discovery with Biomarker Identification Moritz Kircher, M.D., Ph.D., Assistant Professor, Department of Radiology, Center for Molecular Imaging & Nanotechnology, Memorial Sloan Kettering Cancer Center Robert Loberg, Director, Therapeutic Area Lead, Oncology Biomarkers, Amgen 10:45 Spotlight Presentation Breakthroughs in Biomarker Identification 11:15 Surface-Enhanced Resonance Raman Spectroscopy (SERRS) Nanoparticles for High Precision Cancer Imaging Moritz Kircher, M.D., Ph.D., Assistant Professor, Department of Radiology, Center for Molecular Imaging & Nanotechnology, Memorial Sloan Kettering Cancer Center 11:45 Improving Discovery with Oncology Biomarkers Robert Loberg, Director, Therapeutic Area Lead, Oncology Biomarkers, Amgen 12:15 Technology Workshop 12:45 Luncheon in the Poster and Exhibit Hall 1:55 Chairperson s Remarks Jason Baum, Associate Director, Companion Diagnostics, Merrimack Pharmaceuticals Predictive Biomarkers for Targeted Therapies 2:00 Using Targeted Therapies to Overcome Biomarkers of Chemoresistance Jason Baum, Associate Director, Companion Diagnostics, Merrimack Pharmaceuticals 2:30 Design, Implementation, and Analysis of Predictive Biomarker Endpoints for Clinical Studies Samuel DePrimo, Principal Scientist, Johnson & Johnson 3:00 Using Circulation Tumor DNA for Early Detection and Diagnosis Bin Li, Associate Director, Biomarker Development, Novartis 3:30 Networking and Refreshment Break in Poster and Exhibit Hall Utilizing Liquid Biopsies to Advance Biomarker Identification and Diagnostics 4:00 Detecting Expression of Oncology Targets in CTCs and Tumor Samples Steven Pirie-Shepherd, Ph.D., Director, Global R&D, Oncology Research Unit, Pfizer, Inc 4:30 EFIRM-Liquid Biopsy David Wong, Professor, Associate Dean for Research, Director for UCLA Center for Oral/Head & Neck Oncology Research (COOR), Felix and Mildred Yip Endowed Chair in Dentistry, UCLA School of Dentistry 5:00 Networking Reception in Poster and Exhibit Hall *Schedule subject to change
8:00 Chairperson s Opening Remarks Sanjay Khare, Ph.D., President and CEO, ImmunGene, Inc. 8:15 Next Generation Targeted Protein Therapeutics Sanjay Khare, Ph.D., President and CEO, ImmunGene, Inc. 9:00 Integrating Cancer Genomics into the Clinical Workflow David Roth, Director, Precision Medicine Program, Perelman School of Medicine, University of Pennsylvania 9:45 Networking Refreshment Break and Poster & Exhibit Viewing Genome Editing Applications in 10:15 Implementing Genome Editing Tools to Advance Precision Medicine Belen Carrillo-Rivas, Head R&D Innovation Projects, Biotherapeutics R&D, Worldwide Research & Development, Pfizer, Inc 10:45 Spotlight Presentation 11:15 Leveraging Genome Editing to Accelerate Discovery Efforts Belen Carrillo-Rivas, Head R&D Innovation Projects, Biotherapeutics R&D, Worldwide Research & Development, Pfizer, Inc Jacob Corn, Managing Director and Scientific Director, Innovative Genomics Initiative, Assistant Professor, University of California, Berkeley 11:45 Technology Workshop 12:15 Luncheon in Networking and Exhibit Hall 1:25 Chairperson s Remarks Aris N. Economides, Ph.D., Executive Director; Genome Engineering Technologies, and Skeletal Diseases TFA Co-founder & Head of Functional Modeling; Regeneron Genetics Center Regeneron Pharmaceuticals, Inc. Think Tank 1:30 Translating Precision Medicine into Viable Therapeutic Candidates Where Do We Go from Here? This interactive format is a moderator-led, attendee driven conversation focused on brainstorming solutions and strategies for the major challenges and roadblocks with utilizing precision medicine techniques to develop viable therapeutic candidates. Alexander S. Parker, Ph.D., Cecilia and Dan Carmichael Family Associate Director for the Center for Individualized Medicine in Florida, Vice Chair, Department of Health Sciences Research, Mayo Clinic 3:00 Networking Refreshment Break in Poster and Exhibit Hall Accelerating Discovery and Development through Genomics 3:30 The ACVR1R206H Receptor Intracellular Mutation Causes Fibrodysplasia Ossificans Progressiva by Re-Interpreting its Natural Antagonist, Activin A, as an Agonist Aris N. Economides, Ph.D., Executive Director; Genome Engineering Technologies, and Skeletal Diseases TFA Co-founder & Head of Functional Modeling; Regeneron Genetics Center Regeneron Pharmaceuticals, Inc. 4:00 Chemically Synthesized D-Proteins as a New Class of Pharmaceutical Products Dana Ault-Riche, Chief Executive Officer, Reflexion Pharmaceuticals 4:30 Using Precision Gene Editing in Human Disease Jacob Corn, Managing Director and Scientific Director, Innovative Genomics Initiative, Assistant Professor, University of California, Berkeley 5:00 Close of Conference FRIDAY, NOVEMBER 6, 2015 7:30 Registration and Coffee 8:00 Chairperson s Opening Remarks Think Tank 8:15 Leveraging Biomarkers for Precision Medicine This interactive format is a moderator-led, attendee driven conversation focused on brainstorming solutions and strategies for the major challenges and roadblocks with using biomarkers to advance precision medicine. 9:45 Networking Refreshment Break and Poster & Exhibit Viewing Utilizing Big Data to Accelerate 10:15 Spotlight Presentation 10:45 Transforming Biomarker Profiling and Clinical Data Into Personalized Treatment Selection Tool Onco Kem : Lessons Learnt From an Innovative Multi Centric International Clinical Trial Mohammad M. Afshar, CEO, Ariana Pharma 11:15 Understand How Big Data Optimizes Biomarker Discovery Amin Zia, Staff Scientist, Computational Biology, Standard Center for Genomics and Personalized Medicine, Stanford University 11:45 Technology Workshop 12:15 Luncheon in Networking and Exhibit Hall 1:25 Chairperson s Remarks Christos Hatzis, Assistant Professor, Medicine, Director, Bioinformatics, Breast Medical Oncology, Yale University School of Medicine 1:30 Exploring Novel Treatment Strategies in Triple Negative Breast Cancer Christos Hatzis, Assistant Professor, Medicine, Director, Bioinformatics, Breast Medical Oncology, Yale University School of Medicine 2:15 Generation of Custom Monoclonal Antibodies for Therapeutic Purpose at M.D. Anderson Cancer Center Core Laura Bover, Director, Monoclonal Antibody Core Facility, Immunology-Genomics Medicine, University of Texas MD Anderson Cancer Center 3:00 Networking Refreshment Break in Poster and Exhibit Hall Utilizing Biomarkers with microrna and ncrna 3:30 Circulating Biomarker Discovery: from Protein to microrna Xuemei Zhao, Research Fellow, Merck 4:00 MicroRNA Biomarkers for Colorectal Cancer Ajay Goel, Ph.D., Investigator, Director, Center for Gastrointestinal Research, Director, Center for Epigenetics, Cancer Prevention and Cancer Genomics, Baylor Research Institute and Charles A. Sammons Cancer Center, Baylor University Medical Center 4:30 Leveraging Cell-Free Biomarkers to Discover Treatments at an Earlier Stage Ajay Goel, Ph.D., Investigator, Director, Center for Gastrointestinal Research, Director, Center for Epigenetics, Cancer Prevention and Cancer Genomics, Baylor Research Institute and Charles A. Sammons Cancer Center, Baylor University Medical Center Xuemei Zhao, Research Fellow, Merck 5:00 Close of Conference *Schedule subject to change
Propelling Discovery through Genomic Data Advances in Biomarkers and Breakthrough Therapeutics November November 9-10, 2015 5-6, Hyatt 2015 Regency Hilton Reston San Reston, Francisco VA Union Square Hotel San Francisco, CA Combine Genomic Data with Biomarker Discovery to Develop Next-Generation Disease Treatments n I Improve discovery efforts by applying best practices and lessons learned from recent biomarker and genomic projects n I Gain solutions to your current discovery challenges by participating in the interactive Think Tank audience discussions featuring industry experts as moderators n I Jump start your next collaboration or partnership by networking with industry leaders across all phases of genomic and biomarker discovery Propelling Discovery through Genomic Data Advances in Biomarkers and Breakthrough Therapeutics November November 9-10, 2015 5-6, Hyatt 2015 Regency Hilton Reston San Reston, Francisco VA Union Square Hotel San Francisco, CA Forward-Thinking Experts Accelerate Innovative Ideas into Effective Treatments Predicting Responses to Immunotherapy Gary C. Starling, Ph.D. Merck Research Laboratories Using Big Data to Interpret Genomes for Diagnosis, Therapeutics, and Precision Medicine Rong Chen, Ph.D. Icahn School of Medicine, Mount Sinai Generation of Custom Monoclonal Antibodies for Therapeutic Purpose at M.D. Anderson Cancer Center Core Laura Bover University of Texas, MD Anderson Cancer Center Integrating Cancer Genomics into the Clinical Workflow David Roth Perelman School of Medicine, University of Pennsylvania Exploring Novel Treatment Strategies in Triple Negative Breast Cancer Christos Hatzis Yale University School of Medicine Download the Full Agendas and Register Today: n n Next Generation Targeted Protein Therapeutics Sanjay Khare, Ph.D. ImmunGene, Inc. REGISTER by August 28, 2015 and SAVE $ 200